|
|
 |
|
Viewing report
|
|
|
|
Company Financials: Cougar Biotechnology, Inc.
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
Cougar Biotechnology (Cougar) is a development-stage biopharmaceutical company that acquires and develops clinical stage drugs for the treatment of cancer.
Cougar's oncology portfolio include CB7630, for the treatment of advanced prostate cancer patients; CB3304, for the treatment of hematological malignancies; and CB1089, for the treatment of prostate cancer.
Key reasons to purchase this title
- Access important financial information and analysis on the company in a single datapack
- Understand the financial evolution of the five company over the last years.
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Company Financials: Exelixis
Company Financials: Dendreon Corporation
Company Financials: Arqule, Inc.
Company Financials: Medivation
Company Financials: CuraGen Corporation
Company Financials: Allos Therapeutics, Inc.
Company Financials: Genzyme Corporation
Company Financials: Biocryst Pharmaceuticals
Company Financials: Amgen, Inc.
Company Financials: ImmunoGen, Inc.
|
|
|
|
